Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity

References

• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al, Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92 - 8; http://dx.doi.org/10.1056/NEJMoa011954; PMID: 11784875
   PubMed Web of Science ®Google Scholar
• Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 2005; 17:1183 - 93; http://dx.doi.org/10.1016/j.cellsig.2005.03.026; PMID: 15982853
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37:Suppl 4 S9 - 15; http://dx.doi.org/10.1016/S0959-8049(01)00231-3; PMID: 11597399
   PubMedGoogle Scholar
• Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004; 22:777 - 84; http://dx.doi.org/10.1200/JCO.2004.08.001; PMID: 14990632
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004; 22:785 - 94; http://dx.doi.org/10.1200/JCO.2004.07.215; PMID: 14990633
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 1983; 80:1337 - 41; http://dx.doi.org/10.1073/pnas.80.5.1337; PMID: 6298788
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res 2000; 6:747 - 53; PMID: 10741693
   PubMed Web of Science ®Google Scholar
• Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13:1552 - 61; http://dx.doi.org/10.1158/1078-0432.CCR-06-1726; PMID: 17332301
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al, FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525 - 31; http://dx.doi.org/10.1016/S0140-6736(09)60569-9; PMID: 19410716
   PubMed Web of Science ®Google Scholar
• Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, et al. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2011; 22:567 - 74; http://dx.doi.org/10.1093/annonc/mdq431; PMID: 20843984
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129 - 39; http://dx.doi.org/10.1056/NEJMoa040938; PMID: 15118073
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497 - 500; http://dx.doi.org/10.1126/science.1099314; PMID: 15118125
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97:643 - 55; http://dx.doi.org/10.1093/jnci/dji112; PMID: 15870435
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2:e17; http://dx.doi.org/10.1371/journal.pmed.0020017; PMID: 15696205
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al, North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380 - 8; http://dx.doi.org/10.1056/NEJMoa0909530; PMID: 20573926
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al, West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121 - 8; http://dx.doi.org/10.1016/S1470-2045(09)70364-X; PMID: 20022809
   PubMed Web of Science ®Google Scholar
• Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, et al. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology 2009; 77:Suppl 1 57 - 68; http://dx.doi.org/10.1159/000258497; PMID: 20130433
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:918 - 27; http://dx.doi.org/10.1200/JCO.2009.25.2890; PMID: 20100958
   PubMed Web of Science ®Google Scholar
• Brockhoff G, Hofstaedter F, Knuechel R. Flow cytometric detection and quantitation of the epidermal growth factor receptor in comparison to Scatchard analysis in human bladder carcinoma cell lines. Cytometry 1994; 17:75 - 83; http://dx.doi.org/10.1002/cyto.990170110; PMID: 8001460
   PubMedGoogle Scholar
• Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64:8919 - 23; http://dx.doi.org/10.1158/0008-5472.CAN-04-2818; PMID: 15604253
   PubMed Web of Science ®Google Scholar
• Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006; 24:5253 - 8; http://dx.doi.org/10.1200/JCO.2006.08.2263; PMID: 17114658
   PubMed Web of Science ®Google Scholar
• Yang WL, Wu CY, Wu J, Lin HK. Regulation of Akt signaling activation by ubiquitination. Cell Cycle 2010; 9:487 - 97; http://dx.doi.org/10.4161/cc.9.3.10508; PMID: 20081374
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27 - 55; http://dx.doi.org/10.1016/0065-2571(84)90007-4; PMID: 6382953
   PubMedGoogle Scholar
• Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006; 3:448 - 57; http://dx.doi.org/10.1038/ncponc0558; PMID: 16894390
   PubMedGoogle Scholar
• Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1084 - 6; http://dx.doi.org/10.1056/NEJM200104053441409; PMID: 11287980
   PubMed Web of Science ®Google Scholar
• Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol Carcinog 1997; 20:251 - 8; http://dx.doi.org/10.1002/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.0.CO;2-9; PMID: 9364215
   PubMed Web of Science ®Google Scholar
• Colomer R, Lupu R, Bacus SS, Gelmann EP. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 1994; 70:819 - 25; http://dx.doi.org/10.1038/bjc.1994.405; PMID: 7947086
   PubMed Web of Science ®Google Scholar
• Doody JF, Wang Y, Patel SN, Joynes C, Lee SP, Gerlak J, et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Mol Cancer Ther 2007; 6:2642 - 51; http://dx.doi.org/10.1158/1535-7163.MCT-06-0506; PMID: 17913857
   PubMed Web of Science ®Google Scholar
• Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005; 65:226 - 35; PMID: 15665299
   PubMed Web of Science ®Google Scholar
• Yoshida T, Okamoto I, Okabe T, Iwasa T, Satoh T, Nishio K, et al. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer 2008; 122:1530 - 8; http://dx.doi.org/10.1002/ijc.23253; PMID: 18033688
   PubMed Web of Science ®Google Scholar
• Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97:1139 - 45; http://dx.doi.org/10.1038/sj.bjc.6604009; PMID: 17940504
   PubMed Web of Science ®Google Scholar
• Tabernero J, Rojo F, Jimenez E, Montaner I, Santome L, Guix M, et al. A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 2003; 22:Abstr 770
   Google Scholar
• Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64:5355 - 62; http://dx.doi.org/10.1158/0008-5472.CAN-04-0562; PMID: 15289342
   PubMed Web of Science ®Google Scholar
• Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004; 10:6487 - 501; http://dx.doi.org/10.1158/1078-0432.CCR-04-0870; PMID: 15475436
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Forster J, Naret C, Evans T, Sulecki M, Lu H, et al. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J Thorac Oncol 2008; 3:258 - 64; http://dx.doi.org/10.1097/JTO.0b013e3181653d1b; PMID: 18317068
   PubMed Web of Science ®Google Scholar
• Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, et al. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res 2007; 13:1540 - 51; http://dx.doi.org/10.1158/1078-0432.CCR-06-1887; PMID: 17332300
   PubMed Web of Science ®Google Scholar
• Ikeda S, Takabe K, Inagaki M, Funakoshi N, Suzuki K, Shibata T. Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas. Pathol Int 2007; 57:268 - 75; http://dx.doi.org/10.1111/j.1440-1827.2007.02093.x; PMID: 17493174
   PubMed Web of Science ®Google Scholar
• Cicenas J, Urban P, Vuaroqueaux V, Labuhn M, Küng W, Wight E, et al. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res 2005; 7:R394 - 401; http://dx.doi.org/10.1186/bcr1015; PMID: 15987444
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65:1642 - 6; http://dx.doi.org/10.1158/0008-5472.CAN-04-4235; PMID: 15753357
   PubMed Web of Science ®Google Scholar